Jose Osorio1, Tina D Hunter2, Anil Rajendra1, Paul Zei3, Joshua Silverstein4, Gustavo Morales1. 1. Arrhythmia Institute at Grandview, Birmingham, AL, USA. 2. CTI Clinical Trial & Consulting Services, Covington, KY, USA. 3. Brigham And Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Mount Carmel Health System, Columbus, OH, USA.
Abstract
INTRODUCTION: Contact force (CF) guided ablation of paroxysmal atrial fibrillation (PAF) with stable catheter-tissue contact optimizes clinical success and may increase an operator's ability to achieve pulmonary vein isolation (PVI) in a single encirclement. First pass PVI reduces procedure time but the relationship with long term clinical success is not well understood. This study evaluated patient characteristics and procedural details as predictors of one-year clinical success after PAF ablation, including first pass isolation. METHODS: Consecutive de novo PAF ablations were performed with a porous tip CF catheter in 2017 and 2018. All ablations used wide-area circumferential ablation, with first pass isolation captured separately for the left and right pulmonary veins (PVs). CF was held between 10-20 g and the catheter was moved every 10-20 s. Radiofrequency energy was set at 40-45 W throughout the atrium. Patient characteristics and procedural details were tested for association with clinical success, defined as freedom from recurrent atrial tachyarrhythmia through one year. RESULTS: A total of 404 patients were included in the study. Clinical success at one year was 86.6%. Achieving first pass isolation on at least one ipsilateral PV pair was the most significant predictor of clinical success (p=0.0126). After controlling for first pass isolation, only recurrence within the 90-day blanking period was independently predictive (p=0.0015). First pass isolation was not associated with early recurrence (p=0.2454). CONCLUSION: In a real-world setting, first pass isolation was highly predictive of 12-month clinical success after CF-guided ablation in a PAF population. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
INTRODUCTION: Contact force (CF) guided ablation of paroxysmal atrial fibrillation (PAF) with stable catheter-tissue contact optimizes clinical success and may increase an operator's ability to achieve pulmonary vein isolation (PVI) in a single encirclement. First pass PVI reduces procedure time but the relationship with long term clinical success is not well understood. This study evaluated patient characteristics and procedural details as predictors of one-year clinical success after PAF ablation, including first pass isolation. METHODS: Consecutive de novo PAF ablations were performed with a porous tip CF catheter in 2017 and 2018. All ablations used wide-area circumferential ablation, with first pass isolation captured separately for the left and right pulmonary veins (PVs). CF was held between 10-20 g and the catheter was moved every 10-20 s. Radiofrequency energy was set at 40-45 W throughout the atrium. Patient characteristics and procedural details were tested for association with clinical success, defined as freedom from recurrent atrial tachyarrhythmia through one year. RESULTS: A total of 404 patients were included in the study. Clinical success at one year was 86.6%. Achieving first pass isolation on at least one ipsilateral PV pair was the most significant predictor of clinical success (p=0.0126). After controlling for first pass isolation, only recurrence within the 90-day blanking period was independently predictive (p=0.0015). First pass isolation was not associated with early recurrence (p=0.2454). CONCLUSION: In a real-world setting, first pass isolation was highly predictive of 12-month clinical success after CF-guided ablation in a PAF population. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Authors: Leon Iden; Sonia Busch; Daniel Steven; Roland R Tilz; Dong-In Shin; K R Julian Chun; Heidi Estner; Felix Bourier; David Duncker; Philipp Sommer; Andreas Metzner; Tilman Maurer; Nils-Christian Ewertsen; Henning Jansen; Andreas Rillig; Victoria Johnson; Till Althoff Journal: Herzschrittmacherther Elektrophysiol Date: 2021-07-26
Authors: Melinda Boussoussou; Bálint Szilveszter; Borbála Vattay; Márton Kolossváry; Milán Vecsey-Nagy; Zoltán Salló; Gábor Orbán; Perge Péter; Piros Katalin; Nagy Klaudia Vivien; Osztheimer István; Pál Maurovich-Horvat; Béla Merkely; László Gellér; Nándor Szegedi Journal: Int J Cardiovasc Imaging Date: 2022-02-09 Impact factor: 2.357
Authors: Jamario Skeete; Parikshit S Sharma; David Kenigsberg; Grzegorz Pietrasik; Ahmed F Osman; Venkatesh Ravi; Jeanne M Du-Fay-de-Lavallaz; Zoe Post; Jeremiah Wasserlauf; Timothy R Larsen; Kousik Krishnan; Richard Trohman; Henry D Huang Journal: J Arrhythm Date: 2022-05-06
Authors: Zoltán Salló; Péter Perge; Bernadett Balogi; Gábor Orbán; Katalin Piros; Szilvia Herczeg; Klaudia Vivien Nagy; István Osztheimer; Pál Ábrahám; Béla Merkely; László Gellér; Nándor Szegedi Journal: Front Cardiovasc Med Date: 2022-07-07